Valproate Dosing Calculator

Rapid loading involves starting divalproex at 20-30 mg/kg/day from the first day of treatment, rather than gradual titration. This achieves therapeutic levels within 1-3 days and produces faster symptom improvement. The approach is well-tolerated and is now standard practice for acute manic episodes in clinical guidelines.

Valproate has the highest teratogenic risk of any antiepileptic drug: 10% major malformation rate (particularly neural tube defects), plus dose-dependent reduction in IQ (6-9 points) and increased risk of autism spectrum disorder in exposed children. It is absolutely contraindicated in pregnancy for bipolar disorder and migraine. For epilepsy, it should only be used if no alternative exists.

Baseline and periodic: CBC with platelets (thrombocytopenia is dose-related), liver function tests (baseline, monthly for 6 months, then every 6-12 months), valproate level, ammonia level (if symptoms suggest encephalopathy). Pregnancy test before starting in women of childbearing potential. Weight monitoring for metabolic effects.

Valproate can cause elevated ammonia levels with or without hepatic dysfunction. Symptoms include lethargy, confusion, and vomiting mimicking hepatic encephalopathy. Risk increases with concurrent topiramate. If symptomatic, check ammonia level, consider dose reduction or discontinuation, and L-carnitine supplementation (50-100 mg/kg/day, max 3 g) may help.

Valproate inhibits the metabolism of lamotrigine (doubles levels — must halve lamotrigine dose), phenobarbital (increases levels 40%), and the active metabolite of carbamazepine. Enzyme inducers (carbamazepine, phenytoin, phenobarbital) decrease valproate levels. Valproate displaces phenytoin from protein binding while inhibiting its metabolism.

Fatal hepatotoxicity is rare (1/50,000 adults) but more common in children under 2 on polytherapy (1/500). Risk factors include young age, developmental delay, metabolic disorders (especially mitochondrial disease), and polytherapy. Monitor LFTs and clinical symptoms (jaundice, malaise, vomiting). Discontinue if ALT >3x ULN with symptoms.

Yes. Weight gain is a common side effect, affecting 10-70% of patients depending on the study. Mechanisms include increased appetite, metabolic changes (hyperinsulinemia, insulin resistance), and potential effects on leptin signaling. Weight gain is dose-related and may contribute to non-adherence. Weight monitoring and dietary counseling are recommended.

Yes. Extended-release divalproex (Depakote ER) has approximately 15% lower bioavailability than delayed-release (Depakote DR). When switching from DR to ER, increase the dose by 8-20% to maintain comparable levels. Dosing frequency also affects peak-to-trough fluctuation, which can influence tolerability.

Free (unbound) valproate levels are indicated when: total level is >75 mcg/mL (saturable protein binding increases free fraction), hypoalbuminemia, renal impairment, pregnancy, concurrent drugs that displace valproate from albumin, or when clinical effect doesn't correlate with total level. Free therapeutic range: approximately 6-22 mcg/mL.